Effect of graft-versus-host disease on anti-tumor immunity

K. L. Schreiber, J. Forman

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

BCL1, a spontaneous B cell leukemia of BALB/c origin, is rejected by C.B-20 (Ighb, H-40b) but not BALB/c (IgHa, H-40a) mice. Adoptive transfer of C.B-20 anti-BCL1 effector cells specific for the minor histocompatibility Ag H-40a protects irradiated C.B-20 but not BALB/c recipients. Because C.B-20 donor cells could potentially generate graft-vs-host disease (GVHD) in BALB/c recipients, we investigated the possibility that GVHD prevents the anti-tumor effect. GVHD was induced in (C.B-20 x B10.D2)F1 [H-2(d), H-40b x H-2(d),H-40b) recipients after injection of B10.D2-primed C.B-20 donor cells. GVHD was indicated by the histologic appearance of tissue sections from C.B-20 donor cells. GVHD was indicated by the histologic appearance of tissue sections from C.B-20→F1 livers, target organs of GVHD, which showed a marked mononuclear cell infiltrate around the portal tracts and central veins. In addition, splenic lymphocytes from these mice had altered CD4/CD8 ratios and were unable to respond to the polyclonal activators Con A and LPS. The mitogen unresponsiveness was at least partially due to the presence of a suppressor cell, because proliferation of normal spleen cells to Con A and LPS was suppressed upon addition of C.B-20→F1 spleen cells. Further immune dysfunction was evident by the inability of T cells from mice with GVHD to generate a CTL response to H-2 alloantigens. Addition of C.B-20→F1 spleen cells to F1 responder cells at the induction of culture did not prevent generation of CTL, indicating that a suppressor cell was not responsible for the lack of CTL activity. In this setting of GVHD, F1 recipients were able to reject BCL1 upon adoptive transfer of C.B-20 anti-BCL1 effector cells. These data indicate that GVHD-induced immune dysfunction does not inhibit the activity of antileukemia T cells.

Original languageEnglish (US)
Pages (from-to)2018-2026
Number of pages9
JournalJournal of Immunology
Volume144
Issue number5
StatePublished - Jan 1 1990

Fingerprint

Graft vs Host Disease
Immunity
Neoplasms
Spleen
Adoptive Transfer
B-Cell Leukemia
T-Lymphocytes
CD4-CD8 Ratio
Histocompatibility
Isoantigens
Mitogens
Veins
Cell Proliferation
Lymphocytes
Transplants
Injections

ASJC Scopus subject areas

  • Immunology

Cite this

Effect of graft-versus-host disease on anti-tumor immunity. / Schreiber, K. L.; Forman, J.

In: Journal of Immunology, Vol. 144, No. 5, 01.01.1990, p. 2018-2026.

Research output: Contribution to journalArticle

Schreiber, K. L. ; Forman, J. / Effect of graft-versus-host disease on anti-tumor immunity. In: Journal of Immunology. 1990 ; Vol. 144, No. 5. pp. 2018-2026.
@article{4e89dd1f2ed94ab49f0cf6b6c3ffab6d,
title = "Effect of graft-versus-host disease on anti-tumor immunity",
abstract = "BCL1, a spontaneous B cell leukemia of BALB/c origin, is rejected by C.B-20 (Ighb, H-40b) but not BALB/c (IgHa, H-40a) mice. Adoptive transfer of C.B-20 anti-BCL1 effector cells specific for the minor histocompatibility Ag H-40a protects irradiated C.B-20 but not BALB/c recipients. Because C.B-20 donor cells could potentially generate graft-vs-host disease (GVHD) in BALB/c recipients, we investigated the possibility that GVHD prevents the anti-tumor effect. GVHD was induced in (C.B-20 x B10.D2)F1 [H-2(d), H-40b x H-2(d),H-40b) recipients after injection of B10.D2-primed C.B-20 donor cells. GVHD was indicated by the histologic appearance of tissue sections from C.B-20 donor cells. GVHD was indicated by the histologic appearance of tissue sections from C.B-20→F1 livers, target organs of GVHD, which showed a marked mononuclear cell infiltrate around the portal tracts and central veins. In addition, splenic lymphocytes from these mice had altered CD4/CD8 ratios and were unable to respond to the polyclonal activators Con A and LPS. The mitogen unresponsiveness was at least partially due to the presence of a suppressor cell, because proliferation of normal spleen cells to Con A and LPS was suppressed upon addition of C.B-20→F1 spleen cells. Further immune dysfunction was evident by the inability of T cells from mice with GVHD to generate a CTL response to H-2 alloantigens. Addition of C.B-20→F1 spleen cells to F1 responder cells at the induction of culture did not prevent generation of CTL, indicating that a suppressor cell was not responsible for the lack of CTL activity. In this setting of GVHD, F1 recipients were able to reject BCL1 upon adoptive transfer of C.B-20 anti-BCL1 effector cells. These data indicate that GVHD-induced immune dysfunction does not inhibit the activity of antileukemia T cells.",
author = "Schreiber, {K. L.} and J. Forman",
year = "1990",
month = "1",
day = "1",
language = "English (US)",
volume = "144",
pages = "2018--2026",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

TY - JOUR

T1 - Effect of graft-versus-host disease on anti-tumor immunity

AU - Schreiber, K. L.

AU - Forman, J.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - BCL1, a spontaneous B cell leukemia of BALB/c origin, is rejected by C.B-20 (Ighb, H-40b) but not BALB/c (IgHa, H-40a) mice. Adoptive transfer of C.B-20 anti-BCL1 effector cells specific for the minor histocompatibility Ag H-40a protects irradiated C.B-20 but not BALB/c recipients. Because C.B-20 donor cells could potentially generate graft-vs-host disease (GVHD) in BALB/c recipients, we investigated the possibility that GVHD prevents the anti-tumor effect. GVHD was induced in (C.B-20 x B10.D2)F1 [H-2(d), H-40b x H-2(d),H-40b) recipients after injection of B10.D2-primed C.B-20 donor cells. GVHD was indicated by the histologic appearance of tissue sections from C.B-20 donor cells. GVHD was indicated by the histologic appearance of tissue sections from C.B-20→F1 livers, target organs of GVHD, which showed a marked mononuclear cell infiltrate around the portal tracts and central veins. In addition, splenic lymphocytes from these mice had altered CD4/CD8 ratios and were unable to respond to the polyclonal activators Con A and LPS. The mitogen unresponsiveness was at least partially due to the presence of a suppressor cell, because proliferation of normal spleen cells to Con A and LPS was suppressed upon addition of C.B-20→F1 spleen cells. Further immune dysfunction was evident by the inability of T cells from mice with GVHD to generate a CTL response to H-2 alloantigens. Addition of C.B-20→F1 spleen cells to F1 responder cells at the induction of culture did not prevent generation of CTL, indicating that a suppressor cell was not responsible for the lack of CTL activity. In this setting of GVHD, F1 recipients were able to reject BCL1 upon adoptive transfer of C.B-20 anti-BCL1 effector cells. These data indicate that GVHD-induced immune dysfunction does not inhibit the activity of antileukemia T cells.

AB - BCL1, a spontaneous B cell leukemia of BALB/c origin, is rejected by C.B-20 (Ighb, H-40b) but not BALB/c (IgHa, H-40a) mice. Adoptive transfer of C.B-20 anti-BCL1 effector cells specific for the minor histocompatibility Ag H-40a protects irradiated C.B-20 but not BALB/c recipients. Because C.B-20 donor cells could potentially generate graft-vs-host disease (GVHD) in BALB/c recipients, we investigated the possibility that GVHD prevents the anti-tumor effect. GVHD was induced in (C.B-20 x B10.D2)F1 [H-2(d), H-40b x H-2(d),H-40b) recipients after injection of B10.D2-primed C.B-20 donor cells. GVHD was indicated by the histologic appearance of tissue sections from C.B-20 donor cells. GVHD was indicated by the histologic appearance of tissue sections from C.B-20→F1 livers, target organs of GVHD, which showed a marked mononuclear cell infiltrate around the portal tracts and central veins. In addition, splenic lymphocytes from these mice had altered CD4/CD8 ratios and were unable to respond to the polyclonal activators Con A and LPS. The mitogen unresponsiveness was at least partially due to the presence of a suppressor cell, because proliferation of normal spleen cells to Con A and LPS was suppressed upon addition of C.B-20→F1 spleen cells. Further immune dysfunction was evident by the inability of T cells from mice with GVHD to generate a CTL response to H-2 alloantigens. Addition of C.B-20→F1 spleen cells to F1 responder cells at the induction of culture did not prevent generation of CTL, indicating that a suppressor cell was not responsible for the lack of CTL activity. In this setting of GVHD, F1 recipients were able to reject BCL1 upon adoptive transfer of C.B-20 anti-BCL1 effector cells. These data indicate that GVHD-induced immune dysfunction does not inhibit the activity of antileukemia T cells.

UR - http://www.scopus.com/inward/record.url?scp=0025348480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025348480&partnerID=8YFLogxK

M3 - Article

C2 - 1968493

AN - SCOPUS:0025348480

VL - 144

SP - 2018

EP - 2026

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -